Accepted Manuscript Cancer-associated fibroblasts attenuate Cisplatin-induced apoptosis in ovarian cancer cells by promoting STAT3 signaling Huan Yan, Bi-Ying Guo, Shu Zhang PII:
S0006-291X(16)30132-2
DOI:
10.1016/j.bbrc.2016.01.131
Reference:
YBBRC 35248
To appear in:
Biochemical and Biophysical Research Communications
Received Date: 15 January 2016 Accepted Date: 21 January 2016
Please cite this article as: H. Yan, B.-Y. Guo, S. Zhang, Cancer-associated fibroblasts attenuate Cisplatin-induced apoptosis in ovarian cancer cells by promoting STAT3 signaling, Biochemical and Biophysical Research Communications (2016), doi: 10.1016/j.bbrc.2016.01.131. This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.
ACCEPTED MANUSCRIPT Cancer-associated fibroblasts attenuate Cisplatin-induced apoptosis in ovarian cancer cells by promoting STAT3 signaling Huan Yan, Bi-Ying Guo and Shu Zhang *
RI PT
Department of Obstetrics and Gynecology,RenJi Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai Key Laboratory of Gynecologic Oncology, Shanghai, China.
SC
*Corresponding authors at: Department of Obstetrics and Gynecology,RenJi Hospital,
M AN U
School of Medicine, Shanghai Jiao Tong University, Shanghai Key Laboratory of Gynecologic Oncology, Shanghai 200127, China. Tel: 86-21-58752345
AC C
EP
TE D
E-mail addresses:
[email protected] (S. Zhang);
ACCEPTED MANUSCRIPT Abstract One of the main reasons for treatment failure in ovarian cancer is acquired drug resistance.
Cancer in
many
fibroblasts
human
(CAFs)
tumors.
are
known
However,
its
to
enhance
contributions
to
RI PT
chemoresistance
associated
chemoresistance acquisition in ovarian cancer are not well understood. Here, we provide the first evidence that the conditioned medium of CAFs (CAFs-CM) could
SC
attenuate the sensitivity to Cisplatin in A2780 and ES2 ovarian cancer cells and
M AN U
protect them from Cisplatin-induced apoptosis. We found the expression level of two anti-apoptotic proteins, Bcl-2 and Survivin, as well as their upstream controller p-STAT3 were significantly increased when ovarian cancer cells were exposed to CAFs-CM. Furthermore, inhibition of STAT3 signaling with Cryptotanshinone could
TE D
down-regulate the expression of Bcl-2 and Survivin, thus weaken the post-target resistance to Cispaltin mediating by CAFs-CM in ovarian cancer cells. In conclusion, our data suggested that CAFs could activate the anti-apoptotic STAT3 signaling,
EP
thereby decrease the Cisplatin-induced apoptosis and promote chemoresistance in
AC C
ovarian cancer.
Keywords: cancer-associated fibroblasts; epithelial ovarian cancer; chemoresistance; apoptosis; STAT3;
ACCEPTED MANUSCRIPT 1.
Introduction
Ovarian cancer is the leading cause of cancer deaths from gynecological malignancy in women and recurrence, chemotherapy-resistance contributes to the high mortality
RI PT
in patients diagnosed with ovarian cancer [1]. Despite significant advances in surgical treatment and Cisplatin-centered chemotherapy of this cancer, 50% to 70% of patients will relapse within one year [2]. When such relapse occurs, in most cases the ovarian
SC
adenocarcinoma cells have acquired a Cisplatin-resistance phenotype and the
M AN U
responsible mechanism remains poorly understood. Several studies have documented that Cisplatin-resistance can arise from increased drug efflux, abnormity of drug target, enhancement of DNA repair,alteration of apoptosis pathways and inactivation of tumor suppressor [2, 3].
TE D
Recently, studies indicated that tumor microenvironment could potentially induce chemoresistance acquisition in tumor cells and the microenvironment has become a major focus in modeling therapeutic response [4]. The cells within the tumor
EP
microenvironment (stroma) include fibroblasts, endothelial cells, adipocytes,
AC C
mesenchymal cells, mesenchymal stem cells and cells from the immune and inflammatory systems. Fibroblasts within tumors have an activated phenotype, which termed cancer-associated fibroblasts (CAFs). CAFs make up the bulk of cancer stroma of many kinds of cancer, most notably breast, prostate and pancreatic carcinoma [5, 6]. Recent research had discovered that CAFs not only played an important role in tumor growth, angiogenesis and dissemination, but also regulated chemoresistance [7, 8]. In the pancreas, CAFs have been shown to enhance
ACCEPTED MANUSCRIPT chemoresistance in a pancreatic carcinoma model via inhibiting expression of Caspases (8, 9, 7 and 3) [9]. Moreover, CAFs in breast cancer have been correlated with the induction of acquired chemoresistance, which has made CAFs a new target in
RI PT
anticancer therapy [10]. Ovarian cancer is one of the most stroma-rich cancers and CAFs are the most abundant. Zhang et al. found a significant association between ovarian CAFs and the
SC
occurrence of lymph node and omentum metastases in clinical samples,
M AN U
demonstrating that ovarian CAFs were related to ovarian cancer progression and patient clinical outcomes [11]. Moreover, Xu et al. and Lai et al. have provided evidence that CAFs isolated from ovarian cancer tissues induced ovarian cancer cells invasion and migration in vitro [12, 13]. In particular, other recent study indicated a
TE D
role of CAFs-secreted cytokines (IL-6, COX-2 and CXCL1) in promoting breast and ovarian carcinoma growth and invasion [14]. CAFs in ovarian carcinoma were shown in those studies to impact tumor
EP
progression and metastasis, however little research has been done to evaluate the role
AC C
of CAFs in ovarian cancer chemoresistance. The aim of the present study was to investigate the possible role of conditioned medium (CM) of CAFs in Cisplatin resistance of ovarian adenocarcinoma cells. Here, we showed for the first time that a significant decrease of Cisplatin-induced apoptosis in A2780 and ES2 ovarian cancer cells incubated in the presence of CAFs-CM. Our results indicate CAFs-CM could protect ovarian cancer cells from apoptosis by activating the anti-apoptotic STAT3 signaling, including the overexpression of Bcl-2 and Survivin and the potential use of
ACCEPTED MANUSCRIPT STAT3 inhibitors (Cryptotanshinone) could overcome ovarian cancer cells resistance to chemotherapy mediated by tumor microenvironment.
2.1 Primary human CAFs isolation and cell culture
RI PT
2. Materials and methods
CAFs were isolated from human ovarian tumor tissues using the method described by
SC
Lai et al [12]. The human epithelial ovarian cancer (EOC) cells (A2780 and ES2)
M AN U
were purchased from the American Type Culture Collection (ATCC, Manassas, VA). CAFs and EOC cells were cultured in RPMI-1640 (Gibco, Foster City, CA, USA) supplemented with 10% (w/v) fetal bovine serum (FBS, Gibco) and 1% penicillin-streptomycin (Gibco). All CAFs used for this study were between passage 3
TE D
and 5.
2.2 Preparation of CAFs conditioned medium (CM)
EP
CAFs-CM was made from the culture of CAFs in RPMI-1640 with 10% of FBS for
AC C
72 h. Then, the CM were collected and centrifuged at 2,000 g to remove cell debris and filtrated with a 0.22-mm filter (Millipore, Bedford, MA, USA). To prepare co-culture CM, CAFs-CM was mixed with fresh RPMI-1640 complete medium at a ratio of 1:1 and 2:1, which were represented by the Mix1:1 and Mix2:1 in the article.
2.3 Immunofluorescence An indirect immunofluorescent labeling technique was used to identify α-SMA and
ACCEPTED MANUSCRIPT Vimentin expression cells using the following primary antibodies: rabbit monoclonal anti-α-SMA (1:100, Abcam, Cambridge, UK) and rabbit monoclonal anti- Vimentin (1:50, Cell Signaling Technology, Beverly, MA, USA) at 4 ℃ overnight, followed
RI PT
by incubating with Alexa Fluor® 488 conjugate goat anti-rabbit IgG (H+L) secondary antibody (1:200, Invitrogen, Carlsbad, CA). Cells were counterstained with DAPI (Invitrogen) and examined under the fluorescence microscope (Leica, Wetzlar, Hesse,
2.4 Cell viability assay
M AN U
SC
Germany).
Cells were seeded in 96-well plates overnight, and then treated with the indicated concentrations of Cisplatin and Cryptotanshinone for 24h. Then cells were incubated
TE D
in CCK8 reagent (Dojindo, Tokyo, Japan) for 2h. The absorbance value was measured at 450 nm by Thermo Scientific Varioskan Flash (Thermo Fisher Scientific, USA) and
EP
the IC50 was calculated by GraphPad Prism 5 software.
AC C
2.5 Western blotting
Western blotting was performed as previously described [15]. Antibodies for western blotting are Cytokeratin-8 (1:1000, Abcam), α-SMA (1:1000, Abcam), caspase-3 (1:1000, Cell Signaling Technology), Bcl-2 (1:1000, Cell Signaling Technology); survivin (1:200; Santa Cruz Biotechnology, Inc., CA, USA); STAT3(1:1000, ProteinTech Group, Chicago, IL, USA), phospho-STAT3 (tyr705) (1:1000, ProteinTech Group); and β-actin (1:1000, Sigma-Aldrich). The blots were incubated
ACCEPTED MANUSCRIPT with species-specific secondary antibodies: IRDye 680 anti-mouse and IRDye 800 anti-rabbit (1:10000, LI-COR, Nebraska, USA). The signals were detected by
RI PT
Odyssey imaging system (LI-COR).
2.6 Flow cytometry
The apoptosis rate was detected by flow cytometry with apoptosis assay kit
SC
(Invitrogen) following instructions of the manufacturer. Brifely, cells cultured in the
M AN U
presence or absence of CAF CM and exposed to Cisplatin and STAT3 inhibitor for 24 hours were collected and washed in PBS. After re-suspended in 100 µl of 1X binding buffer, cells were incubated with fluorescein isothiocyanate (FITC)-conjugated Annexin V and Propidium Iodide for 15 min at room temperature in the dark. Then
Coulter, USA).
TE D
cells were analyzed by FACS Calibur Flow Cytometer using CXP software (Beckman
EP
2.7 STAT3 inhibition
AC C
Cryptotanshinone (Selleck Chemicals, Houston, TX, USA) is a selective STAT3 inhibitor, which inhibits the phosphorylation of STAT3 Tyr705. A2780 and ES2 Cells were treated with different concentrations of Cryptotanshinone for 24h. As Cryptotanshinone was dissolved in DMSO, DMSO was chosen as a negative control.
2.8 Statistical analysis All experiments were repeated at least three times. The data were presented as Mean ±
ACCEPTED MANUSCRIPT SD. Statistical analyses were conducted using SPSS 16.0 software (Chicago, IL, USA). The differences between two groups were analyzed using the double-sided Student’s t-test. Comparisons among three or more groups were evaluated using
RI PT
one-way analysis of variance (ANOVA). *P < 0.05, **P < 0.01 and***